ERCC2 and neoplasm: In multivariate analysis, patients with T3 or T4 tumor, FAS c.-671GG, FAS c.-671GG or AG, GSTM1 present plus XPC c.2815AA, GSTM1 present plus XPD c.934GG, GSTM1 present plus XPD c.2251AA, GSTM1 present plus TP53 c.215CC or GC, XPD c.934GG plus XPF c.2505TT, and XPD c.2251AA plus XPF c.2505TT had up to 2.37 times more chances of evolving to death by any cause than the remaining patients.